The Identification of Novel Prognostic Markers in Melanoma
Launched by ROYAL MARSDEN NHS FOUNDATION TRUST · Oct 26, 2009
Trial Information
Current as of August 25, 2025
Unknown status
Keywords
ClinConnect Summary
Background - The Royal Marsden Hospital and the Institute of Cancer Research constitute the largest comprehensive cancer centre in Europe. In addition to an in-house drug development program, phase I - phase III clinical trials of novel anti-cancer agents are hosted. In order to investigate the optimal use of novel molecularly targeted agents, access to clinical tumour samples is needed in order to determine which particular cancer type expresses a molecular "signature" that may indicate potential therapeutic utility. Understanding such signatures should accelerate the registration of new d...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosis of melanoma
- • Adequate paraffin-embedded material available for analysis.
- • Adequate clinical follow-up information
- • Written informed consent where applicable
- Exclusion Criteria:
- • Inadequate paraffin-embedded material available
- • Inadequate clinical follow-up information.
About Royal Marsden Nhs Foundation Trust
The Royal Marsden NHS Foundation Trust is a leading cancer treatment and research institution in the UK, renowned for its commitment to advancing oncology through innovative clinical trials and cutting-edge therapies. With a multidisciplinary team of experts, the Trust integrates patient care with groundbreaking research, fostering a collaborative environment to improve outcomes for cancer patients. As a pioneer in the field, the Royal Marsden actively contributes to the development of new treatment protocols and plays a critical role in translating scientific discoveries into clinical practice, ensuring that patients have access to the latest advancements in cancer care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sutton, Surrey, United Kingdom
Patients applied
Trial Officials
Professor Martin Gore
Principal Investigator
Royal Marsden NHS Foundation Trust
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials